Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy

Human Mutation

Volumn 35, Issue 5, 2014, Pages 575-584

  Li, Jie ^a   Yang, Lixin ^b   Gaur, Shikha ^b   Zhang, Keqiang ^b   Wu, Xiwei ^b   Yuan, Yate Ching ^b   Li, Hongzhi ^b   Hu, Shuya ^b   Weng, Yaguang ^a   Yen, Yun ^b,c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

BRCA1; Cisplatin resistance; Gain of function; TP53

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; GAMMA HISTONE H2AX; HISTONE H2AX; PROTEIN P53; UNCLASSIFIED DRUG; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CODON; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; PHENOTYPE; PRIORITY JOURNAL; RNA SEQUENCE; TP53 P R273C GENE; TP53 P.R273G GENE; TP53 P.R273H GENE; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; BREAST NEOPLASMS; CHEMISTRY; DRUG RESISTANCE; FEMALE; GENETICS; MUTATION; PATHOLOGY; PROTEIN CONFORMATION; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTATION; NEOPLASM INVASIVENESS; PROTEIN CONFORMATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898804974     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22528     Document Type: Article

References (30)

1. Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, Aaronson SA, Lee SW. 2000. Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol 20:7450-7459.
2. Brosh R, Rotter V. 2009. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701-713.
3. Caestecker KW, Van de Walle GR. 2012. The role of BRCA1 in DNA double-strand repair: past and present. Exp Cell Res 319:575-587.
4. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
5. Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK. 2008. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 68:4580-4587.
6. Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N. 2007. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis 24:471-483.
7. Freed-Pastor WA, Prives C. 2012. Mutant p53: one name, many proteins. Genes Dev 26:1268-1286.
8. Frgala T, Kalous O, Proffitt RT, Reynolds CP. 2007. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 6:886-897.
9. Hartman AR, Ford JM. 2003. BRCA1 and p53: compensatory roles in DNA repair. J Mol Med (Berl) 81:700-707.
10. Humphrey W, Dalke A, Schulten K. 1996. VMD: visual molecular dynamics. J Mol Graph 14:33-38, 27-28.
11. Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M. 2012. Overexpression of p53 protein in human tumors. Med Mol Morphol 45:115-123.
12. Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, Haffty B, Xia F. 2011. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 71:5546-5557.
13. Joukov V, Chen J, Fox EA, Green JB, Livingston DM. 2001. Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development. Proc Natl Acad Sci USA 98:12078-12083.
14. Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. 2005. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 110:139-153.
15. Kim E, Deppert W. 2004. Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem 93:878-886.
16. Kim E, Deppert W. 2007. Interactions of mutant p53 with DNA: guilt by association. Oncogene 26(15):2185-2190.
17. Kuo ML, den Besten W, Thomas MC, Sherr CJ. 2008. Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle 7(21):3378-3387.
18. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6):861-872.
19. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, et al. 2009. Mutant p53 drives invasion by promoting integrin recycling. Cell 139(7):1327-1341.
20. Oren M, Rotter V. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2(2):a001107.
21. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622-629.
22. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K. 2005. Scalable molecular dynamics with NAMD. J Comput Chem 26(16):1781-1802.
23. Roch-Lefevre S, Mandina T, Voisin P, Gaetan G, Mesa JE, Valente M, Bonnesoeur P, Garcia O, Roy L. 2010. Quantification of gamma-H2AX foci in human lymphocytes: a method for biological dosimetry after ionizing radiation exposure. Radiat Res 174(2):185-194.
24. Roy R, Chun J, Powell SN. 2012. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1):68-78.
25. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. 2005. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25(22):10097-10110.
26. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6(12):909-923.
27. Weisz L, Oren M, Rotter V. 2007. Transcription regulation by mutant p53. Oncogene 26(15):2202-2211.
28. Wright JD, Lim C. 2007. Mechanism of DNA-binding loss upon single-point mutation in p53. J Biosci 32(5):827-839.
29. Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell DI, Hochhauser D, Hartley JA. 2012. gamma-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from two Phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res.
30. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP, Windle B, Deb S. 2012. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33(2):442-451.